BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2816118
Number of visits today
1284
Number of downloads
2065786
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Alhaj-Suliman SO, Wafa EI, Salem AK. Engineering nanosystems to overcome barriers to cancer diagnosis and treatment. Adv Drug Deliv Rev 2022;189:114482. [PMID: 35944587 DOI: 10.1016/j.addr.2022.114482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Alhaj-Suliman SO, Naguib YW, Wafa EI, Saha S, Ebeid K, Meng X, Mohammed HH, Abuo-Rahma GEA, Yang S, Salem AK. A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer. Biomaterials 2023;296:122093. [PMID: 36965280 DOI: 10.1016/j.biomaterials.2023.122093] [Reference Citation Analysis]
2 Ferreira MD, Duarte J, Veiga F, Paiva-Santos AC, Pires PC. Nanosystems for Brain Targeting of Antipsychotic Drugs: An Update on the Most Promising Nanocarriers for Increased Bioavailability and Therapeutic Efficacy. Pharmaceutics 2023;15. [PMID: 36840000 DOI: 10.3390/pharmaceutics15020678] [Reference Citation Analysis]
3 Afonin KA, Dokholyan NV. Editorial to "Molecular engineering of biomaterials programmed to operate in living systems". Adv Drug Deliv Rev 2023;193:114669. [PMID: 36529189 DOI: 10.1016/j.addr.2022.114669] [Reference Citation Analysis]
4 Chen J, Cong X. Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects. Biomed Pharmacother 2023;157:113998. [PMID: 36399829 DOI: 10.1016/j.biopha.2022.113998] [Reference Citation Analysis]
5 Beretta GL. Nanostrategies: The Future Medicine for Fighting Cancer Progression and Drug Resistance 2.0. Int J Mol Sci 2022;23. [PMID: 36430963 DOI: 10.3390/ijms232214486] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345